Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25202244 | 0.81 | EGLN2 (0.33) | EGLN2HPGDSKDM4ENSD2ALDH1A1 | |
| SCHEMBL21017039 | 0.75 | MAPT (0.34) | KDM1AHTTKDM4ENSD2ALDH1A1 | |
| SCHEMBL25815572 | 0.74 | KDM4E (0.33) | HTTKDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL18081458 | 0.74 | KDM4E (0.33) | HTTCSNK1DCSNK1EKDM4ENSD2 | |
| SCHEMBL25804634 | 0.73 | MAOA (0.34) | KDM4E | |
| Hydrochloric Acid SCHEMBL29134748 | 0.72 | KDM4E (0.43) | HTTKDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL23717462 | 0.71 | OPRK1 (0.34) | HTTKDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL25481645 | 0.71 | HTT (0.33) | HTTKDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL19836557 | 0.71 | OPRK1 (0.32) | GRM4HTTKDM4ENSD2ALDH1A1 | |
| SCHEMBL25152682 | 0.70 | HTT (0.32) | HTTKDM4ENSD2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026753-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024238793-A1 | FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER | RGENTA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118871445-A | Fused triazinone derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023086959-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026753-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | SF3B5, RBM17, SF3A2 | KDM1A 4000/4885GRM4 3243/4885HTT 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.